Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699550 | 0.94 | GLP1R (0.54) | GLP1RCA1CA2CTSSCTSK | |
| SCHEMBL3485167 | 0.91 | GLP1R (0.51) | GLP1RCA1CA2ADORA1MEN1 | |
| SCHEMBL3486505 | 0.91 | GLP1R (0.51) | GLP1RCA1CA2ADORA1MEN1 | |
| SCHEMBL16326830 | 0.90 | GLP1R (0.50) | GLP1RCA1CA2ADORA1MEN1 | |
| SCHEMBL13936449 | 0.87 | GLP1R (0.55) | GLP1RCA1CA2MEN1GAA | |
| SCHEMBL13936444 | 0.87 | GLP1R (0.55) | GLP1RCA1CA2MEN1GAA | |
| SCHEMBL13936447 | 0.87 | GLP1R (0.55) | GLP1RCA1CA2MEN1GAA | |
| SCHEMBL13936445 | 0.87 | GLP1R (0.55) | GLP1RCA1CA2MEN1GAA | |
| SCHEMBL3485748 | 0.86 | GLP1R (0.45) | GLP1RCA1CA2ADORA1MEN1 | |
| SCHEMBL3485751 | 0.86 | GLP1R (0.45) | GLP1RCA1CA2ADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885CA1 3988/4885CA2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.